CD8A and posterior cortical atrophy: More importantly, the UBC9 inhibitor 2-D08 combined with the PD-1 blocking antibody substantially enhanced CD8+ T cell cytotoxicity and improved the effectiveness of PCa therapy (Figure 7J).